Cargando…

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial

The impact of antipsychotic drug treatment on sexual function was investigated during a randomised trial comparing first generation antipsychotics (FGAs) to (nonclozapine) second generation antipsychotics (SGAs). Sexual function and quality of life were (rater-blind) assessed in 42 patients with DSM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoud, Ahmed, Hayhurst, Karen P., Drake, Richard J., Lewis, Shôn W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428616/ https://www.ncbi.nlm.nih.gov/pubmed/22937269 http://dx.doi.org/10.1155/2011/596898

Ejemplares similares

Validity of subjective versus objective quality of life assessment in people with schizophrenia
por: Hayhurst, Karen P, et al.
Publicado: (2014)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Liu-Seifert, Hong, et al.
Publicado: (2009)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari, Sulaiman, et al.
Publicado: (2015)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Management of antipsychotic-related sexual dysfunction
por: Rodrigues, C.
Publicado: (2022)

A community pharmacist's intervention in antipsychotic drug‐induced sexual dysfunction in a patient with schizophrenia
por: Maehara, Masaki, et al.
Publicado: (2021)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang, Xinyu, et al.
Publicado: (2019)

Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia
por: Jiang, Ping, et al.
Publicado: (2021)

Influence of Antipsychotic Agents on the Sexuality of Patients Diagnosed with Schizophrenia
por: Fares, Jaballah, et al.
Publicado: (2023)

Antipsychotic-Induced Sexual Dysfunction and Its Management
por: Park, Yeon Won, et al.
Publicado: (2012)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Yeh, Tzu-Pei, et al.
Publicado: (2021)

Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
por: Kang, Seung-Gul, et al.
Publicado: (2021)

T6. SECOND GENERATION ANTIPSYCHOTIC DRUGS AND MORTALITY: A META-ANALYSIS OF PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIALS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
por: Moncrieff, Joanna, et al.
Publicado: (2019)

Executive Dysfunction among Children with Antipsychotic Treated Schizophrenia
por: Wiguna, Tjhin, et al.
Publicado: (2014)

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia
por: Freyberg, Zachary, et al.
Publicado: (2017)

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?
por: Venkatasubramanian, Ganesan, et al.
Publicado: (2013)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia
por: Washida, Kenji, et al.
Publicado: (2013)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
por: Fulone, Izabela, et al.
Publicado: (2021)

Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2021)

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
por: Fabrazzo, Michele, et al.
Publicado: (2022)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

Arterial Stiffness in Patients Taking Second-generation Antipsychotics
por: Fındıklı, Ebru, et al.
Publicado: (2016)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
por: Caruso, Giuseppe, et al.
Publicado: (2020)

Effectiveness of second generation antipsychotics: A systematic review of randomized trials
por: Johnsen, Erik, et al.
Publicado: (2008)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tsmbqanic29j7f9d6pfflc8tjk